What do systematic reviews say?

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in death compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.09 [0.96, 1.24]
  2010 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 2.54 [1.56, 4.12]
  15 studies · 1666 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 910 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal may leads to lower graft loss compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.85 [0.74, 0.98]
  16 studies · 2090 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal may leads to lower adverse events: hypertension compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.82 [0.71, 0.95]
  950 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.87 [0.52, 1.45]
  7 studies · 608 participants
  Low

Calcineurin inhibitor (CNI) withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.1 [0.93, 1.3]
  6 studies · 1079 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal showed no clear difference in acute rejection: avoidance compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 2.16 [0.85, 5.49]
  3 studies · 238 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal probably leads to higher acute rejection: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 3.21 [1.59, 6.48]
  12 studies · 1428 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 242 participants
  Very low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 668 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal showed no clear difference in graft loss: avoidance compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.96 [0.79, 1.16]
  4 studies · 566 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal probably leads to lower graft loss: late withdrawal compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.72, 0.97]
  13 studies · 1831 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.99 [0.69, 1.4]
  23 studies · 5427 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.43 [1.15, 1.78]
  30 studies · 5903 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.94 [0.75, 1.19]
  25 studies · 5446 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.86 [0.64, 1.15]
  7 studies · 2207 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… probably leads to lower adverse events: CMV Infection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.6 [0.44, 0.82]
  13 studies · 2503 participants
  Moderate

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.69 [0.47, 1]
  14 studies · 3699 participants
  Low

Calcineurin inhibitor (CNI) withdrawal + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: lymphocele compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.45 [0.95, 2.21]
  8 studies · 1926 participants
  Low